idecabtagene vicleucel + ciltacabtagene autoleucel + axicabtagene ciloleucel

**Idecabtagene vicleucel + ciltacabtagene autoleucel + axicabtagene ciloleucel** is a hypothetical combination of three distinct **CD19-directed CAR T-cell therapies** administered together for enhanced antitumor activity in B-cell malignancies. **Idecabtagene vicleucel (ide-cel, Abecma)**, developed by **Bristol Myers Squibb and 2seventy bio**, uses a 4-1BB costimulatory domain; **ciltacabtagene autoleucel (cilta-cel, Carvykti)**, from **Janssen (Johnson & Johnson) and Legend Biotech**, features dual B-cell maturation antigen (BCMA)-targeting with a 4-1BB domain but overlaps CD19 engineering in some constructs; and **axicabtagene ciloleucel (axi-cel, Yescarta)**, by **Kite Pharma (Gilead Sciences)**, employs a CD28 costimulatory domain for rapid T-cell activation. No clinical trials or approved use exist for this exact trio, as combining multiple autologous CAR T products poses manufacturing, toxicity (e.g., compounded cytokine release syndrome), and efficacy challenges; each is individually FDA-approved for relapsed/refractory multiple myeloma (ide-cel, cilta-cel primarily BCMA) or large B-cell lymphoma (axi-cel).[1][2]